Lizhuo Pharmaceutical Technology: Empagliflozin Intermediate 3 CAS NO. 1279691-36-9

Product Name:Empagliflozin Intermediate 3

Image: https://www.abnewswire.com/upload/2025/02/244d490e8e67be1fc6fd489f30405e07.jpg

CAS NO.:1279691-36-9

Synonyms:

Empagliflozin N-1;

(2S,3R,4S,5S,6R)-2-(3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)-4-chlorophenyl)-tetrahydro-6-(hydroxyMethyl)-2-Methoxy-2H-pyran-3,4,5-triol;

Methyl 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]Methyl]phenyl]-alpha-D-glucopyranoside;

Related Categories:Empagliflozin intermediates; pharmaceutical raw materials; pharmaceutical intermediates; organic intermediates.

Appearance: White to Off-White solid

Purity: 98%

Application: Empagliflozin intermediates;pharmaceutical intermediate

Supply Ability

Empagliflozin Intermediate3 CAS NO.1279691-36-9 is our regularly production product, whether you need small sample or a large cargo of more than tonnage, our company can supply it formally

If you are interested in Empagliflozin Intermediate3 CAS NO.1279691-36-9, feel freely contact us please, and we will provide you the best quality products, reasonable price and best service, expecting to our cooperation.

Company Profile

Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. is a subsidiary of Shenzhen Rich Chemical Technology Co., Ltd., located in Shanghai. Since its establishment, Lizhuo Pharmaceutical has been committed to providing global pharmaceutical companies and new drug research and development institutions with comprehensive solutions from early product development to drug listing. R&D, customization and production services of pharmaceutical intermediates and APIs required in the life cycle.

Lizhuo Pharmaceutical is a comprehensive technology enterprise focusing on the R&D, production and sales of pharmaceutical intermediates, mainly developing and producing anti-tumor, psychotropic, antiviral, hypoglycemic and antibacterial pharmaceutical intermediates. Our company also engaged in developing innovative drug intermediates according to the situation of the new drug market, and at the same time, develop and customize new drug intermediates according to the needs of customers.

Company Culture [https://www.shlzpharma.com/about-us/]

Lizhuo Pharmaceutical has always adhered to the principle of "keeping promises and honoring promises" and the business philosophy of "excellence, continuous improvement, innovation and development, openness and sharing", striving to provide professional and fast technology and production services, and striving to be a first-class pharmaceutical intermediate and API companies.

Our company has a complete R&D, pilot and scale-up production base. Currently, we have one 1,000-square-meter R&D laboratory, 2 pilot production workshops in Wuhan, equipped with twenty 50L-1000L reactors, high and low temperature Circulation device (-40 degrees C-200 degrees C), ultra-low temperature reaction device (-120 degrees C), vacuum and atmospheric distillation tower (2-6 meters), molecular distillation, solid distillation and other advanced equipment, can undertake ultra-low temperature reaction, format Continuous reaction, nitration reaction, nitro reduction reaction, epoxidation synthesis reaction, solid-liquid distillation and rectification and other production processes, the research and development center can undertake the customization of pharmaceutical intermediates from grams to kilograms, and the pilot production workshop and factory can Produce hundreds of kilograms to tons of products.

The researchers of Lizhuo Pharmaceutical are all doctoral and master technicians who have been engaged in the pharmaceutical synthesis business for many years. They have certain research and achievements in the technical field, and they also have rich practical experience in engineering amplification. At the same time, we also cooperate with Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, School of Pharmacy, Zhejiang University, School of Pharmacy, Zhejiang University of Technology and other institutions to develop projects, so as to promote the research and development of new drugs faster and better, and have achieved a number of research results.

Media Contact
Company Name: Shanghai Lizhuo Pharmaceutical Technology Co.,Ltd.
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lizhuo-pharmaceutical-technology-empagliflozin-intermediate-3-cas-no-1279691369]
Country: China
Website: https://www.shlzpharma.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.